Pharmaceutical Executive-09-01-2022

DE&I in Pharma Sales & Marketing: ‘While There’s Work, There’s Promise’

September 09, 2022

Executive Roundtable

42

9

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.

The Manufacturing Edge on Path to Market

September 09, 2022

Features

42

9

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants

September 09, 2022

Features

42

9

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Building a New Legacy

September 09, 2022

Executive Profile

42

9

Pharm Exec catches up with longtime Merck international business leader Kevin Ali to find out how Organon, the ambitious Merck spinoff he formed just over a year ago, has fared so far in delivering on its mission of creating a global leader and difference-maker in women’s health.